ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 640,40
-0,45%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Medicenna Therapeutics Corporation (MDNA)

  7. Medicenna Therapeutics Corporation (MDNA) Actualités

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MDNA
DateHeureSourceTitreSymboleSociété
14/05/202422h29Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/05/202421h42Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MDNAMedicenna Therapeutics Corporation
13/05/202420h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
22/04/202422h40Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h04Edgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNASDAQ:MDNAMedicenna Therapeutics Corporation
09/11/202314h56GlobeNewswire Inc.Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNASDAQ:MDNAMedicenna Therapeutics Corporation
06/11/202313h00GlobeNewswire Inc.Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
03/11/202317h00GlobeNewswire Inc.Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
27/10/202313h55GlobeNewswire Inc.Medicenna Announces Nasdaq Delisting and Cutback of Management TeamNASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202313h00GlobeNewswire Inc.Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202313h15GlobeNewswire Inc.Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202313h07GlobeNewswire Inc.Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202313h00GlobeNewswire Inc.Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
28/09/202323h00GlobeNewswire Inc.Medicenna Announces Results of Annual and Special Meeting of ShareholdersNASDAQ:MDNAMedicenna Therapeutics Corporation
28/09/202313h00GlobeNewswire Inc.Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
06/09/202313h00GlobeNewswire Inc.Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MDNAMedicenna Therapeutics Corporation
28/08/202313h00GlobeNewswire Inc.Medicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
14/08/202313h00GlobeNewswire Inc.Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters ManagementNASDAQ:MDNAMedicenna Therapeutics Corporation
08/08/202313h00GlobeNewswire Inc.Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee NASDAQ:MDNAMedicenna Therapeutics Corporation
04/08/202313h00GlobeNewswire Inc.Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023NASDAQ:MDNAMedicenna Therapeutics Corporation
01/08/202315h30GlobeNewswire Inc.Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in OncologyNASDAQ:MDNAMedicenna Therapeutics Corporation
28/07/202313h00GlobeNewswire Inc.Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational HighlightsNASDAQ:MDNAMedicenna Therapeutics Corporation
25/07/202313h00GlobeNewswire Inc.Medicenna Presents at National Brain Tumor Society's Research Round TableNASDAQ:MDNAMedicenna Therapeutics Corporation
05/07/202313h00GlobeNewswire Inc.Medicenna Extends Period to Exercise Certain WarrantsNASDAQ:MDNAMedicenna Therapeutics Corporation
27/06/202314h00GlobeNewswire Inc.Medicenna Reports Fiscal Year 2023 Financial Results and Operational HighlightsNASDAQ:MDNAMedicenna Therapeutics Corporation
27/04/202317h11Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MDNAMedicenna Therapeutics Corporation
27/04/202313h00GlobeNewswire Inc.Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price RequirementNASDAQ:MDNAMedicenna Therapeutics Corporation
18/04/202313h00GlobeNewswire Inc.Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:MDNAMedicenna Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MDNA

Dernières Valeurs Consultées

ASX
ME1OD
Melodiol Global Health
UPBT
SUIKRW
SUI Network
LSE
17KM
Investec Bnk 25
NYSE
SF-D
Stifel Financial
COIN
BTNUSD
TSXV
AWE.P@OL
BIT
P10QH3
Bnp Paribas Issuance
NASDAQ
SGGG
ASX
KAT
Katana Capital
BOV
I1SR34
Intuitive Surgical
COIN
NEXTCUSD
Connext
BIT
F18693
Vontobel Financial Produ...
LSE
36AZ
Sthn.pac 5a2aa
NASDAQ
RSMVX
William Blair Small-Mid ...
ASX
PTG
PropTech
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés